Zhejiang Cheng Yi Pharmaceutical Co., Ltd.

SHSE:603811 Stock Report

Market Cap: CN¥2.6b

Zhejiang Cheng Yi Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Zhejiang Cheng Yi Pharmaceutical has been growing earnings at an average annual rate of 3.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 0.8% per year. Zhejiang Cheng Yi Pharmaceutical's return on equity is 13.3%, and it has net margins of 22.7%.

Key information

3.9%

Earnings growth rate

3.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-0.8%
Return on equity13.3%
Net Margin22.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zhejiang Cheng Yi Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:603811 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2473316629049
30 Jun 2470714927847
31 Mar 2467715625551
31 Dec 2367216324847
30 Sep 2363817324845
30 Jun 2365818725742
31 Mar 2364317226341
31 Dec 2265516227044
30 Sep 2264615525845
30 Jun 2265415726345
31 Mar 2268215427443
31 Dec 2169417128140
30 Sep 2177018132738
30 Jun 2178618034837
31 Mar 2177818635435
31 Dec 2075816534632
30 Sep 2069413533433
30 Jun 2067212631632
31 Mar 2068713232525
31 Dec 1968113131930
30 Sep 1964512529230
30 Jun 1963312027527
31 Mar 1956910322530
31 Dec 185469721026
30 Sep 185149516429
30 Jun 184448413025
31 Mar 183827310619
31 Dec 17341698313
30 Sep 1733569880
30 Jun 1731865780
31 Mar 1733371780
31 Dec 1632168820
31 Dec 1531758910
31 Dec 1432054890
31 Dec 1326636670

Quality Earnings: 603811 has high quality earnings.

Growing Profit Margin: 603811's current net profit margins (22.7%) are lower than last year (27.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 603811's earnings have grown by 3.9% per year over the past 5 years.

Accelerating Growth: 603811's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603811 had negative earnings growth (-4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 603811's Return on Equity (13.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 04:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution